SynthesisWellcome open research2019
Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis.
Synthesis in Wellcome open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis.Wellcome open research · 2019Pooled it
- Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.Lancet (London, England) · 2025Trial
- Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).Scientific reports · 2024Trial
- Comparison of Care Cascade Outcome Measures for Hepatitis C Among Insured US Adults.JAMA network open · 2026Article
- Management of hepatitis C infections among Rohingya refugees, Bangladesh.Bulletin of the World Health Organization · 2026Article
- Targeting the SARS-CoV-2 reservoir in long COVID.The Lancet. Infectious diseases · 2025Review
- Article
- Immunological Characteristics of Patients Receiving Ultra-Short Treatment for Chronic Hepatitis C.Frontiers in cellular and infection microbiology · 2022Article
- County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.Hepatology (Baltimore, Md.) · 2021Article
- Article
- High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study.Open forum infectious diseases · 2021Article
- Host genetics and infectious disease: new tools, insights and translational opportunities.Nature reviews. Genetics · 2021Review
- Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.Wellcome open research · 2021Article
- CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.